The emerging breast cancer epidemic: Early diagnosis and treatment

Breast Cancer Research

Volumn 12, Issue SUPPL. 4, 2010, Pages

  Howell, Anthony ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYPROGESTERONE;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER SCREENING; CANCER SURVIVAL; EARLY DIAGNOSIS; FEMALE; HUMAN; INCOME; MAMMOGRAPHY; BREAST TUMOR; DEVELOPING COUNTRY; ECONOMICS; EPIDEMIC; HEALTH CARE DELIVERY; INCIDENCE;

BREAST NEOPLASMS; DEVELOPING COUNTRIES; EARLY DETECTION OF CANCER; ECONOMICS; EPIDEMICS; FEMALE; HEALTH SERVICES ACCESSIBILITY; HUMANS; INCIDENCE; MAMMOGRAPHY;

EID: 78650853263     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2739     Document Type: Article

References (22)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010,
2. Rastogi T, Hildesheim A, Sinha R. Opportunities for cancer epidemiology in developing countries. Nat Rev Cancer 2004, 4:909-917. 10.1038/nrc1475, 15516963.
3. Igene H. Global health inequalities and breast cancer: an impending public health problem for developing countries. Breast J 2008, 14:428-434. 10.1111/j.1524-4741.2008.00618.x, 18821930.
4. Berry DA, Cronin KA, Plevritis S, Fryback DG, Clarke L, Zelen M, Mandelblatt JS, Yakovlev AY, Habbema JD, Feuer EJ. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005, 353:1784-1792. 10.1056/NEJMoa050518, 16251534.
5. Kalager M, Haldorsen T, Bretthauer M, Hoff G, Thoresen SO, Adami HO. Improved breast cancer survival following introduction of an organised mammography screening program among both screened and unscreened women: a population-based cohort study. Breast Cancer Res 2009, 11:R44. 2750103, 19575807, 10.1186/bcr2331.
6. Blanks RG, Moss SM, McGahan CE, Quinn MJ, Babb PJ. Effect of NHS breast screening programme on mortality from breast cancer in England and Wales, 1990-8: comparison of observed with predicted mortality. BMJ 2000, 321:665-669. 27479, 10987769, 10.1136/bmj.321.7262.665.
7. Thomas DB, Gao DL, Ray RM, Wang WW, Allison CJ, Chen FL, Porter P, Hu YW, Zhao GL, Pan LD, Li W, Wu C, Coriaty Z, Evans I, Lin MG, Stalsberg H, Self SG. Randomised trial of breast self-examination in Shanghai: final results. J Natl Cancer Inst 2002, 94:1445-1457.
8. Yip CH, Smith RA, Anderson BO, Miller AB, Thomas DB, Ang ES, Caffarella RS, Corbex M, Kreps GL, McTiernan A. Guideline implementation for breast healthcare in low and middle income countries: early detection resource allocation. Cancer 2008, 113:2244-2256. 10.1002/cncr.23842, 18837017.
9. Love RR. Defining a global research agenda for breast cancer. Cancer 2008, 113:2366-2371. 2603276, 18837032, 10.1002/cncr.23831.
10. Barton MB, Frommer M, Shafiq J. Role of radiotherapy in cancer control in low-income and middle-income countries. Lancet Oncol 2006, 7:584-595. 10.1016/S1470-2045(06)70759-8, 16814210.
11. Bese NS, Munshi A, Budrukkar A, Elzawawy A, Pervez CA. Breast radiation therapy guideline implementation in low and middle income countries. Cancer 2008, 113:2305-2314. 10.1002/cncr.23838, 18837022.
12. Eniu A, Carlson RW, El Saghir NS, Bines J, Bese NS, Vorobiof D, Masettie R, Anderson BO. Guideline implementation for breast healthcare in low and middle income countries: treatment resource allocation. Cancer 2008, 113:2269-2281. 10.1002/cncr.23843, 18837019.
13. Mendis S, Fukino K, Cameron A, Laing A, Fillipe A, Khatib O, Leowski J, Ewen M. The availability and affordability of selected essential medicines for chronic diseases in six low and middle income countries. Bull World Health Organ 2007, 85:279-288. 2636320, 17546309, 10.2471/BLT.06.033647.
14. Steinbrook R. Closing the affordability gap for drugs in low income countries. N Engl J Med 2007, 357:1996-1999. 10.1056/NEJMp0706918, 18003957.
15. Wong NS, Anderson BO, Khoo KS, Ang PT, Yip CH, Lu YS, Shao ZM, Pritchard KI. Management of HER2-positive breast cancer in Asia: consensus statement from Asian Oncology Summit 2009. Lancet Oncol 2009, 10:1077-1085. 10.1016/S1470-2045(09)70230-X, 19880061.
16. Bines J, Eniu A. Effective but cost-prohibitive drugs in breast cancer treatment: a clinician's perspective. Cancer 2008, 113:2353-2358. 10.1002/cncr.23837, 18837028.
17. Badwe RA, Hawaldar RW, Parmar V, Nadkarni M, Shet T, Desai S, Gupta S, Rakesh J, Vanmali V. Single injection depot progesterone prior to surgery and survival in women with operable breast cancer: a randomised controlled trial. Cancer Res 2009, 69(24 Suppl):72.
18. Cuzick J, Dowsett M, Wale C, Salter J, Quinn E, Zabaglo L, Howell A, Buzdar A, Forbes JF. Prognostic value of a combined ER, PgR, Ki67, HER2 immunohistochemical (IHC4) score and comparison with the GHI recurrence score - results from TransATAC. Cancer Res 2009, 69(24 Suppl):74.
19. Love RR, Duc NB, Allred DC, Binh NC, Kha NN, Thuan TV, Mohsin SK, Roanh le D, Khang HX, Tran TL, Quy TT, Thuy NV, The PN, Cau TT, Tung ND, Huong DT, Quang le M, Hien NN, Thuong L, Shen TZ, Xin Y, Zhang Q, Havighurst TC, Yang YF, Hillner BE, DeMets DL. Oophorectomy and tamoxifen adjuvant therapy in premenopausal Vietnamese and Chinese women with operable breast cancer. J Clin Oncol 2002, 20:2559-2566. 10.1200/JCO.2002.08.169, 12011136.
20. Ohno S, Rai Y, Iwata H, Yamamoto N, Yoshida M, Iwase H, Masuda N, Nakamura S, Taniguchi H, Kamigaki S, Noguchi S. Three dose regimens of fulvestrant in postmenopausal Japanese women with advanced breast cancer: results from a double-blind, phase II comparative study (FINDER1). Ann Oncol 2010,
21. Pritchard KI, Rolski J, Papai Z, Mauriac L, Cardoso F, Chang J, Panasci L, Ianuli C, Kahan Z, Fukase K, Lindermann JP, Macpherson MP, Neven P. Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2). Breast Cancer Res Treat 2010,
22. Ragaz J, Wong H. Comparative analysis of breast cancer (BrCa) mortality reduction among regions of Canada between 1950-2004: impact of systemic and diagnostic guidelines after 1977 with a model definition of number of potentially avoided annual deaths (N-PAAD). Cancer Res 2009, 69(24 Suppl):2063.